Interferon: A sharp sword to overcome HCV or HBV-related liver diseases?

Hepatitis Monthly

Volumn 10, Issue 3, 2010, Pages 237-238

  Jia, Wei Dong ^a   Zhang, Chuan Hai ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN P48;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LETTER; LIVER DISEASE;

EID: 77954871123     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Alavian SM, Behnava B, Tabatabaei SV. The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis. Hepat Mon. 2010;10(2):121-31.
2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321(22):1501-6.
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119(4):312-23.
4. Valla DC, Degos F. Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus. J Hepatol. 2001;34(4):606-9.
5. Qian YB, Zhang JB, Wu WZ, et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer. 2006;107(7):1562-9.